Biotechnology
The Menarini Group Announces ELZONRIS® (Tagraxofusp) Designated as an Orphan Drug for BPDCN by Japanese Ministry of Health, Labor and Welfare
* Japanese Ministry of Health, Labor and Welfare grants Orphan Drug Designation to tagraxofusp for blastic plasmacytoid dendritic cell neoplasm (BPDCN) FLORENCE, Italy and NEW YORK, Aug. 30, 2023 /PRNewswire/ -- The Menarini Group ("Menarini"), a leading international pharmaceutical and diagno...
2023-08-30 23:15
2207
European Society of Cardiology Congress: Traditional Chinese Medicine Qili Qiangxin significantly reduces the risk of cardiovascular death and re-hospitalization due to heart failure
AMSTERDAM, Aug. 30, 2023 /PRNewswire/ -- The latest study indicates that adding TCM Qili Qiangxin Capsules (developed and produced by Yiling Pharmaceutical) to the standard of care for heart failure can significantly reduce the risk of re-hospitalization due to worsening heart failure and cardio...
2023-08-30 20:11
1711
GC Biopharma to organize "Donate Blood with Love", a healthy way of giving back to the community
With the participation of all affiliated group entities YONGIN, South Korea, Aug. 30, 2023 /PRNewswire/ --All executives and employees of GC Biopharma, a South Korean biopharmaceutical company, rolled up their sleeves to practice ESG and social value. On Aug. 30th, the company held the "Donate...
2023-08-30 16:05
1382
Asieris Obtained IND Approval from NMPA for APL-1401, a Drug for the Treatment of Moderately-to-Severely Active Ulcerative Colitis
SHANGHAI, Aug. 30, 2023 /PRNewswire/ -- Asieris Pharmaceuticals (688176), a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced that the National Medical Products Adm...
2023-08-30 14:19
1423
InxMed Receives Approval to Initiate Phase I Clinical Trial in China for OMTX705, a First-in-Class FAP-Targeting ADC
NANJING, China, Aug. 29, 2023 /PRNewswire/ -- InxMed, a clinical-stage biotechnology company dedicates on developing innovative therapies targeting drug resistance for hard-to-treat solid tumors，announced today the first-in-class ADC OMTX705 has obtained the IND (Investigational New Drug) approv...
2023-08-30 11:00
1820
Akeso Announced 2023 Interim Results: First Profit, Growing Sales of PD-1/CTLA-4 Bispecific Antibody and Priority Review of PD-1/VEGF
—During the reporting period, Akeso's revenue was RMB3,676.9 million, an increase of 2,154.4% from 2022H1; Akeso recorded a profit ofRMB2,489.5 million. —RMB2,915.2 million was recognized by Akeso as license fee income during the reporting period due to the receipt of an upfront payment equivalen...
2023-08-30 08:03
2265
Epigenic Therapeutics Announces $32 Million in Series A Funding to Bring Breakthrough Epigenome Medicine to Clinical Development
SHANGHAI, Aug. 29, 2023 /PRNewswire/ -- Epigenic Therapeutics, a leading biotechnology company dedicated to developing next-generation gene modulation therapy utilizing epigenome regulation to treat prevalent diseases, today announced that it has raised$32 million in Series A round of financing c...
2023-08-30 08:00
3685
Cerecin to Present New Infantile Spasms Data at the 35th International Epilepsy Congress, Dublin 2023
* Data from the pilot study in infantile spasms showed positive outcomes. * The results will be presented by Cerecin's Chief Medical Officer, Dr. Marc Cantillon on Sunday 2nd September at 2pm (GMT+1). * The Cerecin team will be accompanied by PharmaVentures, who will be supporting Cerecin's ...
2023-08-30 00:04
1673
Cerecin to Present New Infantile Spasms Data at the 35th International Epilepsy Congress, Dublin 2023
* Data from the pilot study in infantile spasms showed positive outcomes. * The results will be presented by Cerecin's Chief Medical Officer, Dr. Marc Cantillon on Sunday 2nd September at 2pm (GMT+1). * The Cerecin team will be accompanied by PharmaVentures, who will be supporting Cerecin's ...
2023-08-30 00:02
1221
Viva Biotech (1873.HK) Announces 2023 Interim Results：Solid Growth in Main Business, Significant Rebound in Profitability
Highlights of the Interim Results as of June 30, 2023: * Revenue reached RMB1,142.2 million, representing a year-on-year increase of approximately 3.0% * Gross profit amounted to RMB406.0 million, representing a year-on-year increase of approximately 17.7% * Adjusted Non-IFRS net profit amo...
2023-08-29 22:38
2553
Akeso Announced Completion of Patient Enrollment in Phase 3 Trial of Ivonescimab (PD-1/VEGF) versus Pembrolizumab in First-line PD-L1 Positive Advanced NSCLC
HONG KONG, Aug. 29, 2023 /PRNewswire/ -- Akeso Inc. ("Akeso", 9926. HK) announced completion of patient enrollment in a head-to-head study of ivonescimab (AK112, PD-1/VEGF bispecific antibody) compared with pembrolizumab as first-line treatment for patients with PD-L1 positive (PD-L1 TPS≥1%) loca...
2023-08-29 20:00
1352
A World's First: The Miss Hong Kong Pageant 2023 Unveiled Contestants' CircleDNA Results Live on Television
* Miss Hong Kong Pageant 2023 winner is Hilary Chong (no. 15) HONG KONG, Aug. 29, 2023 /PRNewswire/ -- In a move that had never been seen before, marrying beauty with science, the Miss Hong Kong Pageant 2023, which justaired on TVB, had set out to revolutionize the industry by partnering with C...
2023-08-29 12:46
2243
Kelun-Biotech Announces Interim Results for 2023: Global Strategic Partnership and Rich Pipeline Boost Significant Revenue Growth in the First Half of the Year
CHENGDU, China, Aug. 28, 2023 /PRNewswire/ -- Today, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech", HKEX: 6990.HK), an innovative biopharmaceutical company focusing on the R&D, manufacturing, commercialization, and international cooperation of biotechnology drugs and innovat...
2023-08-28 22:56
3957
ProfoundBio to Participate in the 21st Annual Morgan Stanley Conference
SEATTLE, Aug. 28, 2023 /PRNewswire/ -- ProfoundBio, a clinical-stage biotechnology company focused on the development of novel antibody-drug conjugate therapeutics for cancer, announced that management will be participating in one-on-one meetings at the Morgan Stanley 21st Annual Global Healthca...
2023-08-28 20:00
1258
Ferinject® granted upgraded recommendations in 2023 ESC heart failure guidelines
The 2023 European Society of Cardiology (ESC) guidelines for acute and chronic heart failure (HF) include upgraded recommendations for intravenous (IV) iron supplementation, including Ferinject® (ferric carboxymaltose), for the management of iron deficiency in patients with HF. Phase IV HEART-FI...
2023-08-28 19:00
2249
Harbour BioMed Announces 2023 Interim Results
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Aug. 28, 2023 /PRNewswire/ -- Harbour BioMed ("HBM", or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology an...
2023-08-28 17:08
2446
Harbour BioMed Announces US IND Clearance of Its First ADC Program HBM9033 in Solid Tumors
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Aug. 28, 2023 /PRNewswire/ -- Harbour BioMed (the"Company", HKEX: 02142) announced that the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application to commence clinical trials of its first antib...
2023-08-28 16:30
1483
Zylox-Tonbridge Reveals 2023 Interim Financial Results: Revenue Surges 50.7% YOY to 230 Million Yuan, Gross Profit Climbs to 171 Million Yuan
HANGZHOU, China, Aug. 27, 2023 /PRNewswire/ -- On August 23rd, 2023, Zylox-Tonbridge Medical Technology Co., Ltd. (2190.HK, hereinafter referred to as "Zylox-Tonbridge" or the "Company") released its financial results for the first half of 2023. The Company's revenue reached230 million yuan, repr...
2023-08-28 11:42
2255
Specialised Therapeutics acquires commercialisation rights to new oral MND therapy
.. ST to partner with Dutch biotech company Treeway BV .. First CNS therapy in ST therapeutic portfolio SINGAPORE, Aug. 27, 2023 /PRNewswire/ -- Independent biopharmaceutical company Specialised Therapeutics Asia Pte Ltd (ST) will partner withNetherlands based biotechnology company Treeway BV to...
2023-08-28 04:00
1629
First participant treated at the highest dose level in Clarity's theranostic prostate cancer trial
Highlights * First participant of cohort 3 in the theranostic SECuRE trial investigating 64Cu/67Cu SAR-bisPSMA in metastatic castrate-resistant prostate cancer (mCRPC) has been treated at the highest dose level of 12GBq. * Cohort 2 was recently completed in 3 participants who received therapy...
2023-08-25 20:58
2706
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 314 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
8005
Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
2024-11-20 09:00
7400